Publications by authors named "Al-Julandani D"
Background: After introducing IL-1/IL-6 inhibitors, some patients with Still and Still-like disease developed unusual, often fatal, pulmonary disease. This complication was associated with scoring as DReSS (drug reaction with eosinophilia and systemic symptoms) implicating these inhibitors, although DReSS can be difficult to recognize in the setting of systemic inflammatory disease.
Objective: To facilitate recognition of IL-1/IL-6 inhibitor-DReSS in systemic inflammatory illnesses (Still/Still-like) by looking at timing and reaction-associated features.
Purpose: To document the long-term visual outcomes in patients with Blau syndrome.
Methods: A retrospective institutional cohort study was conducted, and 13 patients with genetically confirmed Blau syndrome were included. Demographic and clinical data were collected from standardised medical charts.
Objectives: To determine the influence of HLA-B27 positivity on risk of developing chronic nonbacterial osteomyelitis (CNO).
Methods: HLA-B*27 genotype was assessed in 3 European CNO populations and compared with local control populations (572 cases, 33,256 controls). Regional or whole-body MRI was performed at diagnosis and follow-up in all cases which reduces the risk of disease misclassification.
Outcome of adalimumab monotherapy in paediatric non-infectious uveitis.
Pediatr Rheumatol Online J
March 2023
Article Synopsis
- Adalimumab, often used with methotrexate for pediatric non-infectious uveitis, can pose problems for children who can't tolerate methotrexate, leading to the exploration of adalimumab alone as a treatment option.
- In a retrospective study of 28 patients, 82.14% achieved significant disease control without needing additional immunosuppressants while on adalimumab monotherapy.
- The findings suggest that adalimumab alone can effectively manage non-infectious uveitis in children who experience intolerance to combination therapies.
Article Synopsis
- - Adalimumab and its biosimilar Amgevita were compared for their effectiveness and tolerability in treating non-infectious uveitis across three UK medical centers.
- - In a study involving 102 patients, the rates of uveitis flare after switching to Amgevita were similar to those before switching, although intraocular pressure improved.
- - Despite the non-inferiority of Amgevita to Humira, 24% of participants chose to revert to Humira, often due to discomfort from injections and difficulties with the new delivery device.